28.10.2020 Diaceutics PLC, (AIM: DXRX), today announced the launch of DXRX – The Diagnostic Network® which has been designed to accelerate the end-to-end development and commercialization of precision medicine diagnostics by reducing time to peak biomarker test adoption for cancer testing from years to months. As a solution to today’s broken testing ecosystem, DXRX brings together stakeholders from across the industry (laboratories, EQA providers, Cdx manufacturers, and Pharma) to collaborate in a vibrant marketplace to solve real-world testing issues in a secure, standardized way for patients.
The end-to-end service offering provided by DXRX is enabled by a growing network of industry leading service providers in 51 countries. They cover precision medicine diagnostics to deliver implementation services such as test standardization, reimbursement, regulatory support and External Quality Assessment (EQA).
EMQN CIC is proud to be one of the EQA partners on the DXRX platform (read HERE).
For more information: